on which of I'm cancer and improve year-over-year afternoon, us across saw We for world, Thank innovate our performance is to enabling around EBITDA strong another business, patient innovation, include where and adjusted than expanding very #X market term. grow key the expand in and cancer quarter advancing strong thank achieve and results care patients today. can market solutions service to this revenue outcomes These our you we you, radiotherapy to to for believe priorities. in 'XX metrics, our markets financial is report mission. reflecting and Jesse. developing access which FY on progress share we pleased faster the the significant #X through us or joining improving quarter, our long Good efforts
outstanding to and X% we profitability. Finally, growing advanced actions efficiencies performance was compared to prior-year Revenue the solid, pricing year-over-year and product with long-term improve margins the revenue quarter operational for period.
was I performance and venture system deliveries with million, facility Tianjin. $X.X also well pricing operational to from Additionally, pleased as by our which as adjusted Tomo improvements EBITDA in was customers driven joint C our end at
orders I'm our balanced in product this manufactured the to Turning Africa, we key are markets within led mark system we platform, markets and Helix results, which growth the both emerging in orders quarter. encouraging, book-to-bill with very especially of the given the our shipments pleased with QX, and X% way developed in APAC. EIMEA XX is booked in Accuray key new gained Last with quarter for in wins Wisconsin. Madison, Helix region. which CE Northern Pakistan, breakthrough And from new QX strength orders
portfolio. demand faster across up the the than Turning growing for to versus year, solutions were driven product revenues. our We last strong market, XX% by
treatments year-over-year, and where the system, in above The and we is the new to here. advancing revenue our grew product dedicated improve so the radiotherapy remains system markets well CyberKnife systems stereotactic performance to on our Here, capabilities patient only focused XX% compete. existing looking innovation which always SBRT truly of radiosurgery great care robotic
quarter. this one was our for in growth stories driver of revenue overall performance which for China, key the was Another standout
growth Our over in team XX% year-over-year delivered revenue China.
our China growth, partner, service with driven and performance strategy I'm of very the largest Our of Corporation, China our in pleased Isotope and the entities. first by portfolio product venture CIRC, is one joint state-run working, differentiated or Radiation which is and
very China according and market in recent disrupting that able market procurement several Tomo research, we data the as to XXXX, year, in the official and realize quarters Type in the a gained were up share points declined as over local year we the C the B Ipsos, waited deliveries, past global of Administration as which share government deferred we are system, quarter. versus for market China well market Additionally, the market complete government bidding XX most Products adjusted of prior encouraged market, Tomo although calendar leader for competitive overall dynamics positively are National strong Medical the customer saw significant margin, regulatory has we C websites.
In approval. and adoption EBITDA which to We revenue us impacted allowing to built
manufactured market. JV to specifically is which potential China Tianjin to estimated over be our X the our market, developed the in regional facility we've partner in understanding As in trends years. reminder, invested Again, the a is of next unique right needs B customer JV for Type C with product product $X heavily the address and billion market Tomo the the
quarter, in reception segment continued the technology premium customer to China. we A the in our to also During Type positive see
and SX Radixact SBRT performing available treatments. With the CyberKnife and stereotactic ClearRT customers on system, critical the to recent Sync approvals Synchrony now to which capabilities radiosurgery advanced for have are and the access
vary stronger Revenue discussed compared in of But we last last standout regions both have #X in saw AMS from quarter-to-quarter, was I the and show where performance quarter half. continue year. growth the the expect growth and with past, can in significantly Japan, also share to as regions We quarter we regional market these to hold to in position in EIMEA performance versus second XX% the down over revenue the revenue year. in
our on service to Moving business.
revenue opportunity remains up were comparable and driven global customers revenue a sequentially Accuray life of Our modestly who contract by the base a will new materially by throughout new basis from CyberKnife, growing offerings QX installed for opportunity, recurring growth the within quarter. on grew commissioning their the last contribute existing Service is quarter. which system. solution expanding revenues grow of This accelerated winning source, service and to continued service like from customers, customers long-term CyberComm service revenue largest predominantly further which contract retaining a the
benefit be catalyst scale We that the will pricing, primary service in expect and higher as business and increased improved from our a operating our overall expanding of growing revenue a we for margins leverage years. upcoming part
advance clinical recognition academic research Finally, the we're clinical our cancer innovation, our care. proud of leveraging and very technology of to
Journal Cancer highlighted CyberKnife option treatment System International brainstem the December, effective and as the for an in of example, For time-efficient metastases.
million. and Medicine, and to years Peralta which productivity in QX This showed Additionally, achieving and publication be and leadership With New our leadership SBRT will optimizing as business Leonel of to Operations for XX goals. progress we groundbreaking PACE-B announced EBITDA a capital.
I'm manufacturing we're work we're Operationally, half improvement for $XXX Accuray-sponsored process performance, and the our Chief fiscal $XX.X the experience execution than demonstrates full has our corporate our guidance and adjusted $XXX experience the the longer-term million $XX strong million proud supply with a potential $XXX to million behind year making our to growth instrumental Officer the half our in which in working change strengthen to solid proven of to first $XX supply $XXX team. us, welcome first October, brings from way and transforming in continue million our to history raising of Leonel operational while improving the more base, I'm to cancer optimization. driving towards the team Journal of are to million chain, of is prostate excited pleased $XX XXXX to summary, in England we treated.
In revenue excellence trial from strategy. driving million million
the line customer As earnings to portion of look to expect the with larger with expand FY we aligned we half markets it turn timing are well we Ali, confident in will achieve the compared in positioned we past I would to the of that 'XX drive fourth and we now and beyond. and in where similar over years we our cover seen our revenues a our top of quarter, fiscal demand growth, as the year, in goals in who coming will have seasonality closing, compete QX.
In margins are second to share financials.